20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Arena's olorinab improves abdominal pain in Crohn's patients in Phase IIa

Arena Pharmaceuticals Inc. (NASDSAQ:ARNA) said olorinab (APD371) significantly improved average abdominal pain score from baseline to weeks four and eight in a Phase IIa trial to treat abdominal pain in patients with Crohn’s disease. The...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Arena gastrointestinal, cardiovascular, neurology news

Arena will reduce U.S. headcount by about 100 (73%) to about 37 to reduce costs and focus on its clinical-stage pipeline. The cuts will primarily come from research, manufacturing and G&A areas. Arena expects the...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

APD371: Phase Ib started

Arena began a double-blind, placebo-controlled Phase Ib trial to evaluate multiple ascending doses of oral APD371 in 36 healthy volunteers. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif.   Product: APD371   Business: Neurology   Molecular...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Arena pharmaceuticals news

Arena will reduce its U.S. workforce by about 80 (35%) by year end and make additional undisclosed cuts at its Arena Pharmaceuticals GmbH Swiss manufacturing facility. The cuts were brought on by lower than expected...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

APD371: Phase I data

A double-blind, placebo-controlled Phase I trial in 56 healthy volunteers showed that single doses of 10-400 mg oral APD371 were well tolerated. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif.   Product: APD371   Business: Neurology...